Journal
ONCOTARGET
Volume 7, Issue 11, Pages 12904-12916Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.7354
Keywords
NSCLC; metabolomics; biomarkers; early diagnosis; prognosis
Categories
Funding
- Spanish Ministerio de Economia y Competitividad [SAF2014-53977-R, RD12/0036/0025]
- Red Tematica de Investigacion Cooperativa en Cancer (RTICC)
- Instituto de Salud Carlos III (ISCIII)
- Fundacion Mutua Madrilena
Ask authors/readers for more resources
Lung cancer (LC) is responsible for most cancer deaths. One of the main factors contributing to the lethality of this disease is the fact that a large proportion of patients are diagnosed at advanced stages when a clinical intervention is unlikely to succeed. In this study, we evaluated the potential of metabolomics by H-1-NMR to facilitate the identification of accurate and reliable biomarkers to support the early diagnosis and prognosis of non-small cell lung cancer (NSCLC). We found that the metabolic profile of NSCLC patients, compared with healthy individuals, is characterized by statistically significant changes in the concentration of 18 metabolites representing different amino acids, organic acids and alcohols, as well as different lipids and molecules involved in lipid metabolism. Furthermore, the analysis of the differences between the metabolic profiles of NSCLC patients at different stages of the disease revealed the existence of 17 metabolites involved in metabolic changes associated with disease progression. Our results underscore the potential of metabolomics profiling to uncover pathophysiological mechanisms that could be useful to objectively discriminate NSCLC patients from healthy individuals, as well as between different stages of the disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available